| Title： | The CACM experts consensus for Ruyi Zhenbao pill clinical application |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | This consensus is applicable to clinicians (Chinese medicine, western medicine, integrated traditional Chinese and western medicine) in hospitals and primary medical and health institutions at all levels in China, and guides the correct clinical use of Ruyi Zhenbao Pill to treat osteoarthritis and ischemic stroke. |
| Evidence classification method： | This consensus adopts the internationally recognized evidence grading recommendation standard GRADE system. Nominal group method is used to form expert consensus, which mainly considers six factors: evidence quality, curative effect, safety, economy, patient acceptability and others. |
| Development unit： | Wangjing Hospital of Chinese Academy of Traditional Chinese Medicine, Dongzhimen Hospital of Beijing University of Chinese Medicine, Institute of Clinical Basic Medicine of Chinese Academy of Traditional Chinese Medicine, Jinhe Tibetan Medicine Co., Ltd. |
| Registration time: | 2023-02-06 |
| Registration number： | PREPARE-2023CN063 |
| Purpose of the guideline: | To clarify the curative effect, administration scheme and timing, characteristics of dosage and course of treatment, and safety issues of Ruyi Zhenbao Pill in the treatment of osteoarthritis and ischemic stroke, so as to improve the clinical efficacy, promote rational drug use and reduce the risk of drug use. |
